RE: Nmc magazine30 Apr 2024 18:45
Oh come on martinu we've only had 10 years to date from listing (12 in total)
OptiBiotix has established a pipeline of microbiome modulators that impact on energy harvest, appetite
suppression, and lipid and cholesterol management. The development pipeline is fuelled by its proprietary
platform technologies including:
OptiScreen ® : A proprietary high throughput screening and optimisation technology platform designed to
identify microbes within the human microbiome with metabolic pathways which can interact with human
physiological processes and bring health benefits.
OptiBiotic ® : A proprietary platform technology which generates novel compounds and screens them for
their ability to modulate the human microbiome and its microbial end products. This creates the potential to
influence host metabolism and physiology for the prevention and management of disease.
These platforms have been validated in development programmes which have established a pipeline of
compounds which modulate the human microbiome to bring health benefits, including:
● 3 microbial strains which have demonstrated the ability to reduce cholesterol by 71 per cent.,
78 per cent., and 82 per cent., respectively, in laboratory studies;
● An ingredient formulation scientifically formulated by its international key opinion leaders to support
and sustain weight loss in overweight and obese patients. The formulation has been developed so
that components act differently in both their mechanism and site of action; and
● A compound which can selectively enhance the growth of specific microbial species in the human
microbiome. Selectively enhancing specific microbial species creates the capability to modify the human
microbiome specific to health needs.
In summary, the research programme to be followed by OptiBiotix is expected to include:
Cholesterol and lipid management product
The three strains shown to reduce cholesterol in the laboratory will be tested to confirm the absence of
antimicrobial resistance and virulence factors, and to assess gut survivability and manufacturing scale up
capability. On completion of these studies the product will be tested in a human nutritional study to assess
the ability of the product to reduce human cholesterol in at risk populations. Following analysis of the data,
the results will be published in clinical journals.
Microbiome modulator generation and screening
High throughput screening of numerous microbial strains will be used to identify strains with the enzymic
capability of producing novel sugars. Microbial strains with high enzymic activity will be selected and reaction
conditions created to produce sufficient novel sugars for an assessment of their commercial potential,
including:
● identification of novel non-digestible sugars with a sweet taste, low calorific value, and an insulin
independent metabolism with commercial potential as sugar substitutes;
lpldl slimbiome and sweetbiotix
sbtx a